sintilimab + paclitaxel + cisplatin

The combination of sintilimab + paclitaxel + cisplatin is an immunotherapy-chemotherapy regimen that has shown promising results in clinical trials for various cancer types. This combination leverages sintilimab's immune checkpoint inhibition properties alongside the cytotoxic effects of the chemotherapy agents paclitaxel and cisplatin. **Mechanism of Action:** - **Sintilimab**: An anti-PD-1 (programmed cell death protein 1) monoclonal antibody that blocks the interaction between PD-1 and its ligands, enhancing T-cell immune responses against tumor cells. - **Paclitaxel**: A taxane that stabilizes microtubules, preventing their breakdown during cell division, which leads to cell death. - **Cisplatin**: A platinum-based compound that crosslinks DNA, interfering with DNA repair mechanisms and causing apoptosis. The rationale for combining these agents is that chemotherapy may increase tumor antigen release and presentation, potentially enhancing the efficacy of immunotherapy.

Other names

sindilimab + paclitaxel + cisplatinPACS study regimensintilimab plus paclitaxel and cisplatin